Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Plant Cell Rep. 2011 Dec 2;31(3):573–584. doi: 10.1007/s00299-011-1196-6

Fig. 1.

Fig. 1

Facilities for cGMP production of NVCP VLP vaccine and other plant-made pharmaceuticals. (a) The 3600 ft2 BSL-2 greenhouse facility for plant biomass generation and NVCP expression. (b) The Plant Biopharmaceutical Center that houses the Central Bioprocessing Suite, the QA/QC laboratory, and the Process Development laboratory. (c) The floor plan of the Central Bioprocessing Suite. The arrows indicate the unidirectional flow of in-process materials (green), purified final product (red) and people (yellow).